Lastly, SRX3305 significantly inhibited the proliferation of malignant B-cells from Eμ-TCL1 and Eμ-Myc/TCL1 mice ex vivo, suggesting promising therapeutic benefits in aggressive CLL and lymphomas. The gene discussed is MYC; the disease is lymphoma.